云南白药(000538) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 reached ¥9,459,868,782.32, an increase of 0.86% year-over-year[3] - Net profit attributable to shareholders for Q3 2024 was ¥1,137,898,164.95, a decrease of 12.16% compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥1,129,859,005.45, an increase of 1.23% year-over-year[3] - Total operating revenue for Q3 2024 reached CNY 29.92 billion, a slight increase from CNY 29.69 billion in Q3 2023, representing a growth of 0.77%[20] - Net profit attributable to shareholders of the parent company was CNY 4.33 billion, up from CNY 4.12 billion, reflecting an increase of 5.1%[22] - The company reported a basic earnings per share of CNY 2.42, compared to CNY 2.31 in the same period last year, indicating a growth of 4.76%[22] - The company reported a net profit margin of approximately 14.5%, compared to 13.9% in the previous year, indicating improved profitability[22] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥4,073,138,745.34, reflecting a significant increase of 57.29%[3] - The net cash flow from operating activities reached CNY 4,073,138,745.34, an increase of 57.5% compared to CNY 2,589,586,477.11 in Q3 2023[24] - Cash flow from operating activities increased significantly to CNY 32.37 billion, compared to CNY 29.93 billion in the previous year, marking a growth of 8.14%[23] - The total cash outflow from operating activities was CNY 28,799,273,354.03, an increase from CNY 27,815,404,574.07 in Q3 2023[24] - The company reported a net increase in cash and cash equivalents of -CNY 748,958,210.47 for Q3 2024, compared to -CNY 2,464,485.72 in Q3 2023[25] Assets and Liabilities - Total assets as of the end of Q3 2024 amounted to ¥55,612,519,130.18, representing a 3.40% increase from the end of the previous year[3] - The company’s total equity attributable to shareholders was ¥40,522,380,082.77, reflecting a 1.61% increase from the previous year[3] - Total liabilities increased significantly, with other current liabilities rising by 224.47% to CNY 1.73 billion, mainly due to the issuance of short-term financing bonds[6] - The total liabilities increased to CNY 15.07 billion from CNY 13.88 billion, an increase of 8.57% year-over-year[20] - The company’s non-current liabilities totaled 2,100,000.00 CNY, unchanged from the previous period[19] Investments and Expenses - The company reported a significant increase of 927.32% in trading financial assets, totaling ¥1,534,468,794.75, primarily due to the purchase of wealth management products[5] - The construction in progress increased by 66.51% to ¥882,012,011.07, indicating increased investment in ongoing projects[5] - Research and development expenses were CNY 216.18 million, slightly down from CNY 218.61 million, a decrease of 1.11%[21] - Financial expenses decreased by 32.87% to CNY -128.38 million, attributed to reduced interest income and increased interest expenses[6] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 172,527, with the largest shareholder holding 26.18% of the shares[7] - The company has accumulated a total of 17,485,863 shares purchased by the state-owned equity management company, representing about 0.98% of the total issued shares[12] - The company plans to continue share repurchases with a total investment of no less than 500 million CNY and no more than 1 billion CNY over the next six months[11] Other Financial Metrics - The weighted average return on equity for Q3 2024 was 2.84%, a decrease of 0.46 percentage points year-over-year[3] - The company’s inventory impairment loss was CNY -14.01 million, a decline of 207.82% compared to the previous year, indicating improved inventory management[6] - Other income decreased by 51.12% to CNY 56.17 million, mainly consisting of government subsidies[6] - The company reported a net loss from fair value changes of CNY -18.77 million, a decline of 118.11% compared to the previous year, mainly from changes in the fair value of non-current financial assets[6] Corporate Governance - The company has appointed new senior vice presidents, effective from the date of the board meeting on August 26, 2024[16] - The company has renewed its auditing firm for the 2024 fiscal year, ensuring continued compliance and oversight[15]